Aspen Neuroscience Inc, a clinical-stage regenerative medicine biotechnology company developing personalised, autologous cell therapies, announced on Tuesday the completion of dosing in Cohort 3 and Cohort 4 of its ongoing Phase 1/2a ASPIRO clinical trial evaluating sasineprocel (ANPD001) for the treatment of Parkinson's disease (PD).

Aspen says that with the completion of these cohorts, a total of 15 patients have been dosed in the ASPIRO study to date, representing one of the largest clinical experiences reported for an autologous cell therapy in Parkinson's disease.

Cohorts 3 and 4 utilise Aspen's commercial-ready formulation of sasineprocel designed to support scalable, reproducible manufacturing and streamlined clinical delivery. This formulation incorporates a cryopreserved 'thaw-and-inject' drug product, enabling cells to be administered on arrival at the clinical site and increasing procedural efficiency.

The ASPIRO study is an open-label Phase 1/2a clinical trial designed to evaluate the safety, tolerability, and potential efficacy of sasineprocel, an autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuron precursor cell (DANPC) therapy. Sasineprocel is designed to replace and restore damaged neural circuitry in patients with Parkinson's disease without the need for immunosuppressive therapy.

Aspen says that it continues to progress key activities supporting late-stage clinical development, including manufacturing scale-out and process optimisation aligned with future pivotal trial requirements.

Sasineprocel is a single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of PD.